AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31453490 — intervention group
Group type: COMPARATOR
Intervention: Control group (stretching exercises 3 times a week for 3 months, heel lifts, refrain from heavy loading)
Number of subjects: 60
Study 27221118 — intervention group
Group type: COMPARATOR
Intervention: Protein ingestion without sodium nitrate (PRO)
Number of subjects: 24
Study 27221118 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein ingestion with sodium nitrate (PRONO3)
Number of subjects: 24
Study 25761499 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula
Number of subjects: 101
Study 25761499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow-milk formula
Number of subjects: 101
Study 25761499 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 101
Study 23660686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime medication
Number of subjects: 60
Study 23660686 — intervention group
Group type: COMPARATOR
Intervention: Morning medication
Number of subjects: 60
Study 21937486 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermostatic control sterilisation programme (heating water to 65°C during 00:00‐06:00 h and to 50°C from 06:00 to 00:00 h daily)
Number of subjects: 150
Study 21937486 — intervention group
Group type: COMPARATOR
Intervention: Standard control (constant temperature 65°C)
Number of subjects: 150
Study 21937486 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermostatic control sterilisation programme
Number of subjects: 150
Study 21937486 — intervention group
Group type: COMPARATOR
Intervention: Standard control
Number of subjects: 150
Study 21937486 — intervention group
Group type: COMPARATOR
Intervention: Gas consumption per day
Number of subjects: 150
Study 18335154 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine injection into the subcutaneous and muscular layers around the incision site
Number of subjects: 40
Study 18335154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐ and perifacetal joint infiltration with bupivacaine
Number of subjects: 40
Study 17010727 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine jelly instillation (2 mL)
Number of subjects: 34
Study 17010727 — intervention group
Group type: COMPARATOR
Intervention: Control (no jelly instillation)
Number of subjects: 34
Study 12797858 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast awareness and prompt reporting of breast symptoms
Number of subjects: 0
Study 12797858 — intervention group
Group type: COMPARATOR
Intervention: Systematic approach to breast self-examination
Number of subjects: 0
Study 11075961 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 47
Study 11075961 — intervention group
Group type: COMPARATOR
Intervention: No patellar resurfacing (Control)
Number of subjects: 47
Study 8832268 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based exercise program (LBE)
Number of subjects: 41
Study 8832268 — intervention group
Group type: COMPARATOR
Intervention: Water-based exercise program (WBE)
Number of subjects: 41
Study 8832268 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LBE and WBE
Number of subjects: 41
Study 8068604 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional immunoreactive insulin assay
Number of subjects: 803
Study 8068604 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Linco insulin assay
Number of subjects: 803
Study 3284270 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 0.03 mg/kg
Number of subjects: 78
Study 3284270 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 0.03 mg/kg (3-min group)
Number of subjects: 78
Study 3284270 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 0.03 mg/kg (2- and 3-min groups)
Number of subjects: 78
Study 3284270 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline pretreatment)
Number of subjects: 78
Study 30305044 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration training (40 Hz, 4 mm, 360 s, for 12 weeks)
Number of subjects: 12
Study 30305044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 28566523 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-stable lipid emulsion (LE1)
Number of subjects: 50
Study 28566523 — intervention group
Group type: COMPARATOR
Intervention: Acid-unstable lipid emulsion (LE4)
Number of subjects: 50
Study 28566523 — intervention group
Group type: EXPERIMENTAL
Intervention: OCC (13C octanoate)
Number of subjects: 50
Study 28566523 — intervention group
Group type: COMPARATOR
Intervention: ACC (13C sodium acetate)
Number of subjects: 50
Study 28566523 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 50
Study 25556156 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training (12 sessions; 60 min each; 12 weeks)
Number of subjects: 38
Study 25556156 — intervention group
Group type: COMPARATOR
Intervention: Non-training control group
Number of subjects: 38
Study 23777480 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (minimum of 150 minutes of moderate to vigorous intensity exercise per week, aiming for 240 minutes per week for 12 months)
Number of subjects: 60
Study 23777480 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 60
Study 20164319 — intervention group
Group type: EXPERIMENTAL
Intervention: liquid yogurt with a straw
Number of subjects: 105
Study 20164319 — intervention group
Group type: EXPERIMENTAL
Intervention: liquid yogurt with a spoon
Number of subjects: 105
Study 20164319 — intervention group
Group type: EXPERIMENTAL
Intervention: semisolid yogurt with a spoon
Number of subjects: 105
Study 19102186 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint massage (group B)
Number of subjects: 76
Study 19102186 — intervention group
Group type: COMPARATOR
Intervention: Rotatory reduction manipulation (group A)
Number of subjects: 76
Study 16331115 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM) using an OMRON electronic monitor
Number of subjects: 250
Study 16331115 — intervention group
Group type: COMPARATOR
Intervention: Standard health intervention
Number of subjects: 250
Study 14602748 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP
Number of subjects: 43
Study 14602748 — intervention group
Group type: EXPERIMENTAL
Intervention: NFV
Number of subjects: 43
Study 10719812 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 4
Study 10719812 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional anesthesia
Number of subjects: 4
Study 9164003 — intervention group
Group type: EXPERIMENTAL
Intervention: b.i.d. group: one capsule of slow‐release nicardipine, 20 mg, twice a day, three months
Number of subjects: 7274
Study 9164003 — intervention group
Group type: COMPARATOR
Intervention: t.i.d. group: one tablet of regular nicardipine, 20 mg, three times a day, three months
Number of subjects: 7274
Study 1461523 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid input during TPN
Number of subjects: 0
Study 1461523 — intervention group
Group type: EXPERIMENTAL
Intervention: Different amino acid compositions during TPN
Number of subjects: 0
Study 1461523 — intervention group
Group type: EXPERIMENTAL
Intervention: Exponential regression curves
Number of subjects: 0
Study 6237116 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (750 mg/day)
Number of subjects: 20
Study 6237116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (100 mg/day)
Number of subjects: 20
Study 6237116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30762694 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection bupivacaine interscalene block with adjuvant clonidine, dexamethasone, and buprenorphine; multimodal analgesia including acetaminophen, NSAIDs, and opioids.
Number of subjects: 102
Study 29522979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (4000 IU/d) for 3 months
Number of subjects: 13
Study 27305512 — intervention group
Group type: EXPERIMENTAL
Intervention: Euclea natalensis gel
Number of subjects: 10
Study 27305512 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gel applied)
Number of subjects: 10
Study 24310343 — intervention group
Group type: EXPERIMENTAL
Intervention: lutein/zeaxanthin, 10 mg/2 mg
Number of subjects: 4203
Study 24310343 — intervention group
Group type: EXPERIMENTAL
Intervention: lutein/zeaxanthin
Number of subjects: 4203
Study 22290953 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg TID on days 9 to 15
Number of subjects: 75
Study 22290953 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg BID on days 9 to 15
Number of subjects: 75
Study 22290953 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg TID on days 9 to 15
Number of subjects: 75
Study 22290953 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg TID on days 1 to 8
Number of subjects: 75
Study 22290953 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses (400 mg BID and 400 mg TID)
Number of subjects: 75
Study 19943055 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layer running suture
Number of subjects: 248
Study 19943055 — intervention group
Group type: COMPARATOR
Intervention: Interrupted figure-of-eight suture
Number of subjects: 248
Study 19943055 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall major complication rate
Number of subjects: 248
Study 17435541 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 6 mg
Number of subjects: 1212
Study 17435541 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 12 mg
Number of subjects: 1212
Study 17435541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1212
Study 15751772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (once or twice daily)
Number of subjects: 0
Study 15751772 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 0
Study 15751772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with lamivudine and stavudine
Number of subjects: 0
Study 11892685 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic Arnica tablets and herbal Arnica ointment
Number of subjects: 37
Study 11892685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 10459957 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 300 mg tablet twice daily from 36 weeks' gestation and every 3 h from onset of labour until delivery
Number of subjects: 397
Study 10459957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 10459957 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 397
Study 7887759 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group consensus process intervention (1 hour meeting with expert presentation and structured discussion)
Number of subjects: 65
Study 7887759 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated discussion on non-steroidal drug use)
Number of subjects: 65
Study 7887759 — intervention group
Group type: EXPERIMENTAL
Intervention: Prequestionnaires and postquestionnaires measuring influenza knowledge and prevention attitudes
Number of subjects: 65
Study 2242520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg three times daily
Number of subjects: 383
Study 2242520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 111886 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose continuous intravenous insulin infusion
Number of subjects: 58
Study 111886 — intervention group
Group type: COMPARATOR
Intervention: High-dose intermittent subcutaneous injections
Number of subjects: 58
Study 31669447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/day)
Number of subjects: 15804
Study 31669447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15804
Study 28049481 — intervention group
Group type: EXPERIMENTAL
Intervention: RDTs introduced in ADDOs
Number of subjects: 310
Study 28049481 — intervention group
Group type: COMPARATOR
Intervention: Control district (no RDTs introduced)
Number of subjects: 310
Study 25801095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous peginterferon alfa-2a 180 μg, once weekly for 2 weeks
Number of subjects: 0
Study 25801095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous peginterferon alfa-2a 180 μg, twice weekly for 2 weeks
Number of subjects: 0
Study 25801095 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous peginterferon alfa-2a 180 μg, once weekly for 2 weeks
Number of subjects: 0
Study 25801095 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous peginterferon alfa-2a 180 μg, twice weekly for 2 weeks
Number of subjects: 0
Study 25801095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration
Number of subjects: 0
Study 25801095 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 0
Study 23680627 — intervention group
Group type: EXPERIMENTAL
Intervention: Visumax femtosecond platform (Group 1)
Number of subjects: 45
Study 23680627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralase femtosecond platform (Group 2)
Number of subjects: 45
Study 21869697 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 51
Study 21869697 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 51
Study 19630974 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of donepezil with memantine placebo added
Number of subjects: 800
Study 19630974 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to memantine with donepezil placebo added
Number of subjects: 800
Study 19630974 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil and memantine together
Number of subjects: 800
Study 19630974 — intervention group
Group type: COMPARATOR
Intervention: Donepezil placebo with memantine placebo
Number of subjects: 800
Study 19630974 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 800
Study 16713391 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of industrially produced TFA (IP‐TFA)
Number of subjects: 87
Study 16713391 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g n‐3 PUFA
Number of subjects: 87
Study 16713391 — intervention group
Group type: COMPARATOR
Intervention: Control fat
Number of subjects: 87
Study 15295409 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Tc-99m sestamibi lung uptake
Number of subjects: 192
Study 11425821 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg injection of triptorelin (group 1)
Number of subjects: 132
Study 11425821 — intervention group
Group type: COMPARATOR
Intervention: 100 microg triptorelin daily reduced to 50 microg at the start of FSH stimulation (group 2)
Number of subjects: 132
Study 9250557 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50
Study 9250557 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 50
Study 8102890 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection (n=100)
Number of subjects: 200
Study 8102890 — intervention group
Group type: COMPARATOR
Intervention: Axillary biopsy (n=100)
Number of subjects: 200
Study 3304156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin
Number of subjects: 107
Study 3304156 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 107
Study 29499859 — intervention group
Group type: EXPERIMENTAL
Intervention: TRANSTAR operation
Number of subjects: 208
Study 29499859 — intervention group
Group type: COMPARATOR
Intervention: Double TST36 staplers
Number of subjects: 208
Study 27711918 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 660
Study 27711918 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 660
Study 27711918 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 660
Study 27711918 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with laser treatment
Number of subjects: 660
Study 24635756 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ventilatory capacity (forced expiratory volume in 1 second less than lower limit of normal)
Number of subjects: 1635
Study 24635756 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle weakness (maximal inspiratory pressure < lower limit of normal)
Number of subjects: 1635
Study 24635756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea (moderate to severe ratings on the modified Borg index after a 400-m walk test)
Number of subjects: 1635
Study 24635756 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe mobility impairment (Short Physical Performance Battery score ≤ 7)
Number of subjects: 1635
Study 24635756 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow gait speed (400-MWT gait speed <0.8 m/s)
Number of subjects: 1635
Study 24635756 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ventilatory capacity
Number of subjects: 1635
Study 24635756 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle weakness
Number of subjects: 1635
Study 24635756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea
Number of subjects: 1635
Study 21706324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 25 mg/m² intravenously on days 1-3 and gemcitabine 1,000 mg/m² on days 1 and 8, every 3 weeks for two cycles as neoadjuvant chemotherapy, followed by two cycles as adjuvant chemotherapy after radiotherapy.
Number of subjects: 54
Study 21706324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 54
Study 21706324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy
Number of subjects: 54
Study 20167174 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradigm Veo insulin pump with new calibration algorithm
Number of subjects: 72
Study 20167174 — intervention group
Group type: COMPARATOR
Intervention: Paradigm REAL-Time (PRT) sensor-augmented pump system
Number of subjects: 72
Study 18175748 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g vitamin C daily supplementation in humans
Number of subjects: 14
Study 18175748 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.24 mg/cm2 body surface area vitamin C daily supplementation in rats
Number of subjects: 14
Study 17015053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 32
Study 17015053 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin (40 mg)
Number of subjects: 32
Study 15495678 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based program for reducing cardiovascular risk factors, including general CV health classes and follow-up phone calls.
Number of subjects: 0
Study 15495678 — intervention group
Group type: COMPARATOR
Intervention: Control group with limited follow-up.
Number of subjects: 0
Study 10868718 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer of training approach
Number of subjects: 80
Study 10868718 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional approach
Number of subjects: 80
Study 9035634 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidential conversations (experimental group)
Number of subjects: 186
Study 9035634 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (conversations during both measurements)
Number of subjects: 186
Study 9035634 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (no conversations during either measurement)
Number of subjects: 186
Study 1551955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 20
Study 1551955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2859523 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (4000 or 4800 rad)
Number of subjects: 227
Study 2859523 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (fluorouracil and semustine [methyl‐CCNU])
Number of subjects: 227
Study 2859523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiation therapy and chemotherapy
Number of subjects: 227
Study 2859523 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy (control group)
Number of subjects: 227
Study 2859523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiation and chemotherapy
Number of subjects: 227
Study 2859523 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 227
Study 31504395 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block
Number of subjects: 100
Study 31504395 — intervention group
Group type: COMPARATOR
Intervention: Dynamax
Number of subjects: 100
Study 31504395 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 28857683 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Promoting Lifestyle Profile 2 (HPLP2)
Number of subjects: 1200
Study 28857683 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsibility, interpersonal relations, and stress management (dimensions of HPLP2)
Number of subjects: 1200
Study 25348047 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glycaemic control optimization programme (BGCOP)
Number of subjects: 86
Study 25348047 — intervention group
Group type: COMPARATOR
Intervention: Conventional intensive insulin therapy (CIIT)
Number of subjects: 86
Study 24510314 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic intra-arterial fotemustine (HIA) at 100 mg/m² on days 1, 8, 15 (and 22 in HIA arm only) as induction, and after a 5-week rest period every 3 weeks as maintenance.
Number of subjects: 171
Study 24510314 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fotemustine (IV) at 100 mg/m² on days 1, 8, 15 as induction, and after a 5-week rest period every 3 weeks as maintenance.
Number of subjects: 171
Study 22300292 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal regeneration therapy laser
Number of subjects: 35
Study 22300292 — intervention group
Group type: COMPARATOR
Intervention: Control laser (photocoagulation)
Number of subjects: 35
Study 20597707 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 380
Study 18757963 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging external fixation with supplementary Kirschner-wire fixation
Number of subjects: 88
Study 18757963 — intervention group
Group type: COMPARATOR
Intervention: Volar-locked plating with screws
Number of subjects: 88